GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Study Identifies Fatigue as a Key Non-Motor Symptom in Parkinson’s Disease with Neural and Molecular Links

by GOAI
Share To

A recent study has highlighted fatigue as a significant non-motor symptom in Parkinson’s disease (PD), shedding light on its neural and molecular underpinnings. While motor impairments such as tremors and rigidity have traditionally been the primary focus of PD research, this investigation emphasizes the complex nature of fatigue and its substantial impact on patients’ quality of life. Researchers aim to address the gap in understanding this debilitating symptom, which remains a critical challenge for those living with PD.

The study explores the mechanisms behind Parkinson’s-related fatigue, examining both neural pathways and molecular factors that may contribute to its development. By focusing on these aspects, researchers hope to provide insights into how fatigue manifests in PD patients and how it differs from other symptoms associated with the disease. The findings underscore the importance of addressing non-motor symptoms in Parkinson’s treatment strategies, as they play a crucial role in overall patient well-being.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top